Oral News and Research

RSS

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino's expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing.

6 Nov 2014

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Janssen Research & Development, LLC today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO (bedaquiline) in the STREAM Study.

6 Nov 2014

Study measures effects of high-fat maternal diet on the cognitive functioning of offspring

New research suggests that a high-fat maternal diet during pregnancy and while breastfeeding could have significant and lasting detrimental effects on the brain function and behavior of children.

5 Nov 2014

Light-activated diabetes drug: an interview with Dr David Hodson

We've known about chemicals that can be light-activated for about five to ten years now. They’ve mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.

5 Nov 2014

New device facilitates diagnosis of prostate cancer

Distinguishing between benign and malignant prostate tissue is difficult. A new device facilitates the diagnosis for doctors: Through a visual analysis, they can reliably determine if they are dealing with carcinoma within a minute-and-a-half. Fraunhofer researchers will be presenting the prototype at the COMPAMED trade fair in Düsseldorf from November 12th to 14th.

5 Nov 2014

Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan Inc. today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe.

5 Nov 2014

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.

4 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Hemp Health launches CBD wellness supplements

Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness supplements. Available in oil, spray and capsule form, Hemp Health's products offer a compelling alternative to medical marijuana. The CBD supplements provide consumers with the therapeutic ingredient in hemp while allowing them to avoid the negative mental and physical effects of marijuana.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD).

4 Nov 2014

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

New research from CVS Health finds starting a new diabetes patient on metformin, a generic oral diabetes medicine that helps control blood sugar levels, reduced the need to add on additional treatments to control the condition over time. Although there are many classes of oral diabetes medications, there has historically been little evidence available on the comparative effectiveness of treatments to help patients and providers select an initial diabetes therapy.

31 Oct 2014

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of acromegaly, a rare condition caused by excess growth hormone in the blood.

31 Oct 2014

New research shows link between perinatal exposure to BPA and risk of food intolerance in later life

If it seems like more people are allergic to, or intolerant of, more and different kinds of foods than ever before, there might be a reason why. A new research published in November 2014 issue of The FASEB Journal, scientists show, for the first time, that there is a link between perinatal exposure to Bisphenol A (BPA) at low doses and the risk to develop food intolerance in later life.

31 Oct 2014

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

30 Oct 2014

Specific complex carbohydrates in human milk protect against Norovirus

Norovirus is the most common cause of viral epidemic gastroenteritis. About 18% of all gastroenteritis infections are caused by Norovirus affecting 267 million people worldwide every year. According to information of the Robert Koch-Institute more than 200.000 Norovirus-infections were registered in Germany during 2012 and 2013. The Centers for Disease Control and Prevention report up to 21 million Norovirus-infections per year in the USA.

30 Oct 2014

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

The prevalence of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, is increasing rapidly. New research to determine the impact of radioactive iodine (RAI) therapy on survival in PTC, describing a novel blood test able to detect circulating BRAFV600E-positive tumor DNA, and identifying a long non-coding RNA specifically associated with the thyroid that is down-regulated in PTC compared to normal thyroid tissue in patient-derived clinical specimens and cell cultures will be featured in oral presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

New research findings on Graves' disease to be highlighted at ATA meeting

A unique mouse model of Graves' disease, an autoimmune disorder that causes hyperthyroidism, and new research findings that may help improve the treatment of Graves' disease will be highlighted in oral and poster presentations at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

Oral News and Research

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Study measures effects of high-fat maternal diet on the cognitive functioning of offspring

Light-activated diabetes drug: an interview with Dr David Hodson

New device facilitates diagnosis of prostate cancer

Mylan announces U.S. launch of generic Loestrin 24 Fe

Common drug could become the future standard of care for HE patients

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Hemp Health launches CBD wellness supplements

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

New research shows link between perinatal exposure to BPA and risk of food intolerance in later life

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Specific complex carbohydrates in human milk protect against Norovirus

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

Novel therapeutic approaches to improve thyroid cancer outcomes

New research findings on Graves' disease to be highlighted at ATA meeting

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News